86632-95-3

Usage

Chemical classification

Derivative of gamma-aminobutyric acid (GABA)

Receptor interaction

Selective agonist for the GABAB receptor

Primary uses

Muscle relaxant and antispasmodic medication for conditions such as multiple sclerosis, spinal cord injuries, and cerebral palsy

Mechanism of action

Decreases the activity of nerves in the brain and spinal cord, resulting in muscle relaxation and relief from spasticity

Available forms

Oral and intrathecal

Potential side effects

Drowsiness, dizziness, and weakness

Usage guidance

Should be used under the guidance of a healthcare professional

Upstream product

• 98-81-7 1-bromovinylbenzene 
• 6970-60-1 2-N,N-dimethylaminocyclohexanone 

Downstream Products

• 86632-96-4 cis-2-(Methylamino)-1-(1-phenylethenyl)cyclohexanol 

Relevant academic research and scientific papers

Synthesis Applications of Cationic Aza-Cope Rearrangements. Stereoselective synthesis of cis- and trans-3a-Aryl-4-oxodecahydrocycloheptapyrroles

A general synthesis of 3a-aryl-4-oxodecahydrocycloheptapyrroles is detailed (eq 1, n=2).The key step is a "ring-enlarging pyrrolidine annulation" reaction which occurs when 2-amino-1-(1-arylvinyl)cyclohexanols are treated at 25-80 deg C with an aldehyde and acid.Three different methods (Schemes I and II) for assembling the 2-amino-1-(1-arylvinyl)cyclohexanol intermediates are reported. cis-3a-Aryl-4-oxodecahydrocycloheptapyrroles can be formed with complete stereocontrol from either cis- or trans-2-amino-1-(1-arylvinyl)cyclohexanols.The corresponding trans bicyclics can be prepared with modest (ca. 3:1) selectivity from cis-2--1-(1-arylvinyl)cyclohexanols.The stereochemical outcome of these tandem cationic aza-Cope-Mannich cyclization reactions is consistent with chair topographies for the rearrangment steps (Scheme III).